Application of nanomedicine in the thetreatment of melenoma
Advances and prospects
Keywords:
metastasis, early detection, nanoparticle-delivered, PI3K/AktAbstract
Melanoma is the most forceful sort of skin malignant growth and has exceptionally high paces of mortality. A beginning phase melanoma can be carefully eliminated, with an endurance pace of close to 100%. Notwithstanding, metastasized melanoma is challenging to fix. The 5-year endurance rates for patients with metastasized melanoma are still beneath 20%. Metastasized melanoma is presently treated by chemotherapy, designated treatment, immunotherapy and radiotherapy. The result of the majority of the ongoing treatments is not even close to hopeful. Despite the fact that melanoma patients with a transformation include the oncogene v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) have an at first higher positive reaction rate to designated treatment, the greater part create obtained drug obstruction following a half year of the treatment. To increment treatment adequacy, early finding, more powerful pharmacological specialists, and more successful conveyance frameworks are critically required. Nanotechnology has been broadly read up for melanoma treatment and analysis,to diminish drug obstruction, increment helpful viability, and lessen secondary effects. Include this audit, we sum up the new advancement on the improvement of different nanoparticles for melanoma treatment and finding.
Downloads
References
Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220–241.
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.
Jerant AF, Johnson JT, Sheridan CD, Caffrey TJ. Early detection and treatment of skin cancer. Am Fam Physician. 2000;62(2):357–368.
American Cancer Society [homepage on the Internet]. Skin cancer facts. Available from: http://www.cancer.org/cancer/cancercauses/ sunanduvexposure/skin-cancer-facts. Accessed June 5, 2013.
Zitelli JA, Mohs FE, Larson P, Snow S. Mohs micrographic surgery for melanoma. DermatolClin. 1989;7(4):833–843.
Boyle GM. Therapy for metastatic melanoma: an overview and update. Expert Rev Anticancer Ther. 2011;11(5):725–737.
Katipamula R, Markovic SN. Emerging therapies for melanoma. Expert Rev Anticancer Ther. 2008;8(4):553–560.
Khan KH, Goody RB, Hameed H, Jalil A, Coyle VM, McAleer JJ. Metastatic melanoma: a regional review and future directions. Tumori. 2012;98(5):575–580.
Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. LancetOncol. 2003;4(12):748–759.
Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J ExpClin Cancer Res. 2000;19(1):21–34.
Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002;62(23):6997–7000.
Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–954.
Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB, Blum RH. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazinewith tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J ClinOncol. 1998;16(5):1743–1751.
Atkins MB, Hsu J, Lee S, et al; Eastern Cooperative Oncology Group. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J ClinOncol. 2008;26(35):5748–5754.
Sharma A, Sharma AK, Madhunapantula SV, et al. Targeting Akt3 signaling in malignant melanoma using isoselenocyanates. Clin Cancer Res. 2009;15(5):1674–1685.
Bei D, Meng J, Youan BB. Engineering nanomedicines for improved melanoma therapy: progress and promises. Nanomedicine(Lond). 2010;5(9):1385–1399.
Pacheco I, Buzea C, Tron V. Towards new therapeutic approaches for malignant melanoma. Expert Rev Mol Med. 2011;13:e33.
Tran MA, Watts RJ, Robertson GP. Use of liposomes as drug delivery vehicles for treatment of melanoma. Pigment Cell Melanoma Res. 2009;22(4):388–399.
Langer R. Drug delivery and targeting. Nature. 1998;392(6679 Suppl): S5–S10.
Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov. 2003;2(5):347–360.
Prabhakar U, Maeda H, Jain RK, et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 2013;73(8):2412–2417.
Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994;54(4): 987–992.
Moghimi SM, Hunter AC. Capture of stealth nanoparticles by the body’s defences. Crit Rev Ther Drug Carrier Syst. 2001;18(6):527–550.
Prabhu P, Patravale V. The upcoming field of theranosticnanomedicine: an overview. J Biomed Nanotechnol. 2012;8(6): 859–882.
Sharifi S, Behzadi S, Laurent S, Forrest ML, Stroeve P, Mahmoudi M. Toxicity of nanomaterials. ChemSoc Rev. 2012;41(6):2323–2343.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
